{"protocolSection": {"identificationModule": {"nctId": "NCT03730961", "orgStudyIdInfo": {"id": "CV013-034"}, "secondaryIdInfos": [{"id": "2018-000970-31", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Bristol-Myers Squibb", "class": "INDUSTRY"}, "briefTitle": "An Investigational Study of Continuous 8-Hour Intravenous Administrations of BMS-986231 in Participants With Heart Failure and Reduced Heart Function Given a Standard Dose of Loop Diuretic", "officialTitle": "A Randomized, Double-Blind, Placebo-Controlled, Cross-over Phase 2 Study of Continuous 8-Hour Intravenous Infusions of BMS-986231 in Patients With Heart Failure and Impaired Systolic Function Given a Standard Dose of Loop Diuretic"}, "statusModule": {"statusVerifiedDate": "2021-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2019-01-17", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2019-12-11", "type": "ACTUAL"}, "completionDateStruct": {"date": "2020-01-09", "type": "ACTUAL"}, "studyFirstSubmitDate": "2018-11-01", "studyFirstSubmitQcDate": "2018-11-02", "studyFirstPostDateStruct": {"date": "2018-11-05", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2020-12-10", "resultsFirstSubmitQcDate": "2021-01-06", "resultsFirstPostDateStruct": {"date": "2021-01-26", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2021-02-24", "lastUpdatePostDateStruct": {"date": "2021-02-26", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Bristol-Myers Squibb", "class": "INDUSTRY"}}, "oversightModule": {"isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false, "isUsExport": true}, "descriptionModule": {"briefSummary": "The purpose of this study is to investigate continuous 8-hour introductions of BMS-986231 in participants with heart failure and weakened heart function given a standard dose of diuretic."}, "conditionsModule": {"conditions": ["Cardiac Failure", "Myocardial Failure", "Congestive Heart Failure", "Heart Decompensation"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 23, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Placebo+Diuretic to BMS-986231+Diuretic", "type": "EXPERIMENTAL", "description": "Administered in a cross over design with 8-hour continuous infusions and 7-28 day wash-out periods", "interventionNames": ["Drug: BMS-986231", "Drug: Furosemide", "Drug: Placebo"]}, {"label": "BMS-986231+Diuretic to Placebo+Diuretic", "type": "EXPERIMENTAL", "description": "Administered in a cross over design with 8-hour continuous infusions and 7-28 day wash-out periods", "interventionNames": ["Drug: BMS-986231", "Drug: Furosemide", "Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "BMS-986231", "description": "Intravenous administration", "armGroupLabels": ["BMS-986231+Diuretic to Placebo+Diuretic", "Placebo+Diuretic to BMS-986231+Diuretic"]}, {"type": "DRUG", "name": "Furosemide", "description": "Intravenous administration", "armGroupLabels": ["BMS-986231+Diuretic to Placebo+Diuretic", "Placebo+Diuretic to BMS-986231+Diuretic"]}, {"type": "DRUG", "name": "Placebo", "description": "Intravenous administration", "armGroupLabels": ["BMS-986231+Diuretic to Placebo+Diuretic", "Placebo+Diuretic to BMS-986231+Diuretic"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "4-hour Urinary Output Following Intravenous Administration of 40 mg Furosemide to HFrEF Participants Receiving BMS-986231 Infusion Compared to Placebo", "description": "The total volume of urinary output 4 hours after 40 mg furosemide bolus given to participants with HFrEF while on BMS-986231 compared to placebo: absolute difference in total volume and % change from placebo.\n\nSequence 1: Placebo in period 1, drug in period 2\n\nSequence 2: Drug in period 1, placebo in period 2", "timeFrame": "4 hours"}], "secondaryOutcomes": [{"measure": "FeNa in Participants With HFrEF While on BMS-986231 Compared to Placebo", "description": "Secondary efficacy analyses was performed using the randomized population. The FeNa, FeK, furosemide urinary and plasma concentration and the ratio of urinary sodium to urinary furosemide was calculated at each time point over 4-hour urine/plasma collection after a bolus injection of 40 mg furosemide while receiving BMS-986231 or placebo.\n\nFractional Excretion Na = ((Urine Sodium \\* Plasma Creatinine) / (Plasma Sodium \\* Urine Creatinine)) \\* 100", "timeFrame": "Day 1, predose; 0-4 hours, 4-5 hours, 5-6 hours, 6-7 hours, 7-8 hours"}, {"measure": "FeK in Participants With HFrEF While on BMS-986231 Compared to Placebo", "description": "Secondary efficacy analyses was performed using the randomized population. The FeNa, FeK, furosemide urinary and plasma concentration and the ratio of urinary sodium to urinary furosemide was calculated at each time point over 4-hour urine/plasma collection after a bolus injection of 40 mg furosemide while receiving BMS-986231 or placebo.\n\nFractional Excretion K = ((Urine Potassium \\* Plasma Creatinine) / (Plasma Potassium \\* Urine Creatinine)) \\* 100", "timeFrame": "Day 1, predose; 0-4 hours, 4-5 hours, 5-6 hours, 6-7 hours, 7-8 hours"}, {"measure": "Furosemide Urinary Concentrations", "description": "Summary of urine recovery by interval, measured by amount excreted.", "timeFrame": "Day 1, predose, 0-2 hours, 2-4 hours, 4-5 hours, 5-6 hours, 6-7 hours, 7-8 hours, 8-10 hours"}, {"measure": "Furosemide Plasma Concentrations", "description": "Summary of plasma concentrations by interval.", "timeFrame": "Day 1: 4, 5, 6, 8, 10 hours"}, {"measure": "Ratio Urinary Sodium (Na) to Urinary Furosemide at 8 Hours Post-start Infusion", "description": "Summary of urinary concentrations 0-4 hours after furosemide\n\nRatio = Cumulative Sodium Excretion / Cumulative Furosemide in Urine", "timeFrame": "0-4 hours after furosemide"}, {"measure": "Number of Participants With Clinically Relevant Hypotension", "description": "Clinically relevant hypotension is defined as systolic blood pressure (SBP) \\< 90 mmHg or symptomatic hypotension during infusion", "timeFrame": "up to 8 hours"}, {"measure": "Number of Participants With an Adverse Event (AE)", "description": "Clinically relevant hypotension is defined as systolic blood pressure (SBP) \\< 90 mmHg or symptomatic hypotension during infusion", "timeFrame": "up to 8 days"}, {"measure": "Number of Participants With an Abnormal Clinical Laboratory Value", "description": "Number of participants who experienced an in-study abnormal clinical laboratory event under the category of Hematology, Chemistry or Urinalysis.", "timeFrame": "from first dose to 30 days post-last dose (ca. 5-8 weeks)"}, {"measure": "Change From Baseline in Vital Signs - Blood Pressure", "description": "The change in baseline for vital signs was reported for each arm.", "timeFrame": "Day 1, 8 hours post-dose (end of infusion)"}, {"measure": "Change From Baseline in Vital Signs - Heart Rate", "description": "The change in baseline for vital signs was reported for each arm.", "timeFrame": "Day 1, 8 hours post-dose (end of infusion)"}, {"measure": "Change From Baseline in Vital Signs - Oxygen Saturation", "description": "The change in baseline for vital signs was reported for each arm.", "timeFrame": "Day 1, 8 hours post-dose (end of infusion)"}, {"measure": "Change From Baseline in Electrocardiograms (ECGs) - Mean Heart Rate", "description": "The change in baseline for ECGs was reported for each arm.", "timeFrame": "Day 1, 8 hours post-dose (end of infusion)"}, {"measure": "Change From Baseline in Electrocardiograms (ECGs) - PR, QRS Duration, QT, QTcF Intervals", "description": "The change in baseline for ECGs was reported for each arm.", "timeFrame": "Day 1, 8 hours post-dose (end of infusion)"}, {"measure": "Telemetry", "description": "Telemetry data not collected.", "timeFrame": "Day 1, 8 hours post-dose"}, {"measure": "Change From Baseline in Physical Examination - Body Weight", "description": "The change in baseline for physical examinations was reported for each arm.", "timeFrame": "Day 1, 8 hours post-dose (end of infusion)"}]}, "eligibilityModule": {"eligibilityCriteria": "For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com\n\nInclusion Criteria:\n\n* Left ventricular ejection fraction \\<45%, as assessed by echocardiography, a multigated acquisition (MUGA) scan or magnetic resonance imaging (MRI) scan within 18 months\n* On stable chronic guideline-directed therapy for HF including chronic loop diuretics, ACEi, ARBs, MRAs, ARNI or / and \u03b2-blockers as tolerated, with no changes of these medications in the past 2 weeks\n* At least an oral dose of 40 mg of furosemide/day or equivalent (20 mg torsemide, 1 mg bumetamide)\n\nExclusion Criteria:\n\n* SBP \\< 115 mm Hg or \\> 180 mm Hg at screening or pre-randomization\n* Heart rate \\< 50 beats per minute (bpm) or \\> 120 bpm at screening or pre-randomization\n* Primary HF etiology attributable to either restrictive/obstructive cardiomyopathy, idiopathic hypertrophic or uncorrected severe valvular disease\n\nOther protocol defined inclusion/exclusion criteria could apply", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Bristol-Myers Squibb", "affiliation": "Bristol-Myers Squibb", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Glasgow Clinical Research Facility", "city": "Glasgow", "zip": "G51 4TF", "country": "United Kingdom", "geoPoint": {"lat": 55.86515, "lon": -4.25763}}, {"facility": "Richmond Pharmacology", "city": "London", "zip": "SW17 0RE", "country": "United Kingdom", "geoPoint": {"lat": 51.50853, "lon": -0.12574}}]}, "referencesModule": {"references": [{"pmid": "31168885", "type": "DERIVED", "citation": "Felker GM, Borentain M, Cleland JG, DeSouza MM, Kessler PD, O'Connor CM, Seiffert D, Teerlink JR, Voors AA, McMurray JJV. Rationale and design for the development of a novel nitroxyl donor in patients with acute heart failure. Eur J Heart Fail. 2019 Aug;21(8):1022-1031. doi: 10.1002/ejhf.1504. Epub 2019 Jun 6."}], "seeAlsoLinks": [{"label": "BMS Clinical Trial Information", "url": "https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html"}, {"label": "BMS Clinical Trial Patient Recruiting", "url": "https://www.bmsstudyconnect.com/s/US/English/USenHome"}, {"label": "FDA Safety Alerts and Recalls", "url": "https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "23 participants were randomized/assigned to treatment, and 23 initiated period 1 treatment.", "groups": [{"id": "FG000", "title": "Sequence 1", "description": "First received placebo (period 1), then received BMS-986231 (period 2) following washout.\n\nEach treatment administered 8 hours continuous IV infusion at the dose of 12 \u03bcg/kg/min, corresponding to an infusion rate of 20 mL/H. At hour 4 after the start of the infusion, 40 mg IV bolus of furosemide administered through a separate IV line, given slowly over 1 to 2 minutes."}, {"id": "FG001", "title": "Sequence 2", "description": "First received BMS-986231 (period 1), then received placebo (period 2) following washout.\n\nEach treatment administered 8 hours continuous IV infusion at the dose of 12 \u03bcg/kg/min, corresponding to an infusion rate of 20 mL/H. At hour 4 after the start of the infusion, 40 mg IV bolus of furosemide administered through a separate IV line, given slowly over 1 to 2 minutes."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "comment": "Started = Initiated Period 1 treatment", "achievements": [{"groupId": "FG000", "numSubjects": "12"}, {"groupId": "FG001", "numSubjects": "11"}]}, {"type": "Period 1 Completion", "achievements": [{"groupId": "FG000", "numSubjects": "12"}, {"groupId": "FG001", "numSubjects": "11"}]}, {"type": "Period 2 Completion", "achievements": [{"groupId": "FG000", "comment": "1 participant did not complete Period 2 due to hypotension but remained in the study", "numSubjects": "11"}, {"groupId": "FG001", "comment": "1 participant discontinued study due to AE", "numSubjects": "10"}]}, {"type": "COMPLETED", "comment": "Completed study", "achievements": [{"groupId": "FG000", "numSubjects": "12"}, {"groupId": "FG001", "numSubjects": "10"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Sequence 1", "description": "First received placebo (period 1), then received BMS-986231 (period 2) following washout.\n\nEach treatment administered 8 hours continuous IV infusion at the dose of 12 \u03bcg/kg/min, corresponding to an infusion rate of 20 mL/H. At hour 4 after the start of the infusion, 40 mg IV bolus of furosemide administered through a separate IV line, given slowly over 1 to 2 minutes."}, {"id": "BG001", "title": "Sequence 2", "description": "First received BMS-986231 (period 1), then received placebo (period 2) following washout.\n\nEach treatment administered 8 hours continuous IV infusion at the dose of 12 \u03bcg/kg/min, corresponding to an infusion rate of 20 mL/H. At hour 4 after the start of the infusion, 40 mg IV bolus of furosemide administered through a separate IV line, given slowly over 1 to 2 minutes."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "23"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "8"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "15"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "67.7", "spread": "8.19"}, {"groupId": "BG001", "value": "69.8", "spread": "8.23"}, {"groupId": "BG002", "value": "68.7", "spread": "8.10"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "2"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "21"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "23"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "22"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "4-hour Urinary Output Following Intravenous Administration of 40 mg Furosemide to HFrEF Participants Receiving BMS-986231 Infusion Compared to Placebo", "description": "The total volume of urinary output 4 hours after 40 mg furosemide bolus given to participants with HFrEF while on BMS-986231 compared to placebo: absolute difference in total volume and % change from placebo.\n\nSequence 1: Placebo in period 1, drug in period 2\n\nSequence 2: Drug in period 1, placebo in period 2", "populationDescription": "Treated (per Protocol set) - All randomized participants who were given both study treatments and completed the study as per protocol. Participants are included in the treatment group they received in each period.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mL", "timeFrame": "4 hours", "groups": [{"id": "OG000", "title": "BMS-986231", "description": "BMS-986231 administered 8 hours continuous IV infusion at the dose of 12 \u03bcg/kg/min, corresponding to an infusion rate of 20 mL/H. At hour 4 after the start of the infusion, 40 mg IV bolus of furosemide administered through a separate IV line, given slowly over 1 to 2 minutes."}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered 8 hours continuous IV infusion of D5W administered at the flow rate of 20 mL/H. At hour 4 after the start of the infusion, 40 mg IV bolus of furosemide administered through a separate IV line, given slowly over 1 to 2 minutes."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "21"}]}], "classes": [{"title": "Sequence 1", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "900.7", "spread": "366.56"}, {"groupId": "OG001", "value": "1603.3", "spread": "674.18"}]}]}, {"title": "Sequence 2", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1176.7", "spread": "386.21"}, {"groupId": "OG001", "value": "1345.4", "spread": "391.11"}]}]}, {"title": "Total", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "21"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1032.1", "spread": "392.74"}, {"groupId": "OG001", "value": "1480.5", "spread": "559.92"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Drug - placebo", "pValue": "0.0021", "statisticalMethod": "t-test, 2 sided", "paramType": "Mean Difference (Net)", "paramValue": "-448", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-714", "ciUpperLimit": "-183"}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Percent change Drug - placebo", "pValue": "0.0222", "statisticalMethod": "t-test, 2 sided", "paramType": "Mean Difference (Net)", "paramValue": "-22.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-40.7", "ciUpperLimit": "-3.51"}]}, {"type": "SECONDARY", "title": "FeNa in Participants With HFrEF While on BMS-986231 Compared to Placebo", "description": "Secondary efficacy analyses was performed using the randomized population. The FeNa, FeK, furosemide urinary and plasma concentration and the ratio of urinary sodium to urinary furosemide was calculated at each time point over 4-hour urine/plasma collection after a bolus injection of 40 mg furosemide while receiving BMS-986231 or placebo.\n\nFractional Excretion Na = ((Urine Sodium \\* Plasma Creatinine) / (Plasma Sodium \\* Urine Creatinine)) \\* 100", "populationDescription": "All randomized subjects who started study drug infusion in at least one treatment period. This is also known as the Intent to Treat (ITT) population. Data in this data set was analyzed based on randomized sequence of treatments.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percent of filtered sodium", "timeFrame": "Day 1, predose; 0-4 hours, 4-5 hours, 5-6 hours, 6-7 hours, 7-8 hours", "groups": [{"id": "OG000", "title": "BMS-986231", "description": "BMS-986231 administered 8 hours continuous IV infusion at the dose of 12 \u03bcg/kg/min, corresponding to an infusion rate of 20 mL/H. At hour 4 after the start of the infusion, 40 mg IV bolus of furosemide administered through a separate IV line, given slowly over 1 to 2 minutes."}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered 8 hours continuous IV infusion of D5W administered at the flow rate of 20 mL/H. At hour 4 after the start of the infusion, 40 mg IV bolus of furosemide administered through a separate IV line, given slowly over 1 to 2 minutes."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "23"}]}], "classes": [{"title": "Before start of infusion", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.5", "spread": "0.52"}, {"groupId": "OG001", "value": "0.6", "spread": "0.73"}]}]}, {"title": "0-4 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "16"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.6", "spread": "0.67"}, {"groupId": "OG001", "value": "0.7", "spread": "0.84"}]}]}, {"title": "4-5 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "17"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.6", "spread": "3.34"}, {"groupId": "OG001", "value": "5.4", "spread": "3.09"}]}]}, {"title": "5-6 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "5.0", "spread": "2.87"}, {"groupId": "OG001", "value": "7.0", "spread": "3.51"}]}]}, {"title": "6-7 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "18"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "3.3", "spread": "2.33"}, {"groupId": "OG001", "value": "4.7", "spread": "2.79"}]}]}, {"title": "7-8 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "15"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.7", "spread": "1.26"}, {"groupId": "OG001", "value": "3.3", "spread": "2.52"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Drug - placebo, 0-4 hours after furosemide", "pValue": "0.0163", "statisticalMethod": "t-test, 2 sided", "paramType": "Mean Difference (Net)", "paramValue": "-4.25", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-7.63", "ciUpperLimit": "-0.876"}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Percent change Drug - placebo, 0-4 hours after furosemide", "pValue": "0.2018", "statisticalMethod": "t-test, 2 sided", "paramType": "Mean Difference (Net)", "paramValue": "-15", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-38.8", "ciUpperLimit": "8.77"}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Drug - placebo, 0-8 hours after start of infusion", "pValue": "0.0526", "statisticalMethod": "t-test, 2 sided", "paramType": "Mean Difference (Net)", "paramValue": "-3.61", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-7.27", "ciUpperLimit": "0.0446"}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Percent change Drug - placebo, 0-8 hours after start of infusion", "pValue": "0.2076", "statisticalMethod": "t-test, 2 sided", "paramType": "Mean Difference (Net)", "paramValue": "-14.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-38.8", "ciUpperLimit": "9"}]}, {"type": "SECONDARY", "title": "FeK in Participants With HFrEF While on BMS-986231 Compared to Placebo", "description": "Secondary efficacy analyses was performed using the randomized population. The FeNa, FeK, furosemide urinary and plasma concentration and the ratio of urinary sodium to urinary furosemide was calculated at each time point over 4-hour urine/plasma collection after a bolus injection of 40 mg furosemide while receiving BMS-986231 or placebo.\n\nFractional Excretion K = ((Urine Potassium \\* Plasma Creatinine) / (Plasma Potassium \\* Urine Creatinine)) \\* 100", "populationDescription": "All randomized subjects who started study drug infusion in at least one treatment period. This is also known as the Intent to Treat (ITT) population. Data in this data set was analyzed based on randomized sequence of treatments.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percent of filtered potassium", "timeFrame": "Day 1, predose; 0-4 hours, 4-5 hours, 5-6 hours, 6-7 hours, 7-8 hours", "groups": [{"id": "OG000", "title": "BMS-986231", "description": "BMS-986231 administered 8 hours continuous IV infusion at the dose of 12 \u03bcg/kg/min, corresponding to an infusion rate of 20 mL/H. At hour 4 after the start of the infusion, 40 mg IV bolus of furosemide administered through a separate IV line, given slowly over 1 to 2 minutes."}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered 8 hours continuous IV infusion of D5W administered at the flow rate of 20 mL/H. At hour 4 after the start of the infusion, 40 mg IV bolus of furosemide administered through a separate IV line, given slowly over 1 to 2 minutes."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "23"}]}], "classes": [{"title": "Before start of infusion", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.4", "spread": "0.16"}, {"groupId": "OG001", "value": "0.4", "spread": "0.17"}]}]}, {"title": "0-4 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "16"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.5", "spread": "0.20"}, {"groupId": "OG001", "value": "0.4", "spread": "0.17"}]}]}, {"title": "4-5 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "17"}, {"groupId": "OG001", "value": "17"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.1", "spread": "0.67"}, {"groupId": "OG001", "value": "0.9", "spread": "0.46"}]}]}, {"title": "5-6 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.2", "spread": "0.54"}, {"groupId": "OG001", "value": "1.2", "spread": "0.52"}]}]}, {"title": "6-7 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "16"}, {"groupId": "OG001", "value": "18"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.1", "spread": "0.42"}, {"groupId": "OG001", "value": "1.0", "spread": "0.35"}]}]}, {"title": "7-8 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "15"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.0", "spread": "0.32"}, {"groupId": "OG001", "value": "0.8", "spread": "0.32"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Drug - placebo, 0-4 hours after furosemide", "pValue": "0.1621", "statisticalMethod": "t-test, 2 sided", "paramType": "Mean Difference (Net)", "paramValue": "0.431", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.189", "ciUpperLimit": "1.05"}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Percent change Drug - placebo, 0-4 hours after furosemide", "pValue": "0.0338", "statisticalMethod": "t-test, 2 sided", "paramType": "Mean Difference (Net)", "paramValue": "32", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "2.72", "ciUpperLimit": "61.3"}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Drug - placebo, 0-8 hours after start of infusion", "pValue": "0.0600", "statisticalMethod": "t-test, 2 sided", "paramType": "Mean Difference (Net)", "paramValue": "0.766", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.0353", "ciUpperLimit": "1.57"}, {"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Percent change Drug - placebo, 0-8 hours after start of infusion", "pValue": "0.0280", "statisticalMethod": "t-test, 2 sided", "paramType": "Mean Difference (Net)", "paramValue": "33.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "4.02", "ciUpperLimit": "63"}]}, {"type": "SECONDARY", "title": "Furosemide Urinary Concentrations", "description": "Summary of urine recovery by interval, measured by amount excreted.", "populationDescription": "All randomized subjects who started study drug infusion in at least one treatment period. This is also known as the Intent to Treat (ITT) population. Data in this data set was analyzed based on randomized sequence of treatments.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg", "timeFrame": "Day 1, predose, 0-2 hours, 2-4 hours, 4-5 hours, 5-6 hours, 6-7 hours, 7-8 hours, 8-10 hours", "groups": [{"id": "OG000", "title": "BMS-986231", "description": "BMS-986231 administered 8 hours continuous IV infusion at the dose of 12 \u03bcg/kg/min, corresponding to an infusion rate of 20 mL/H. At hour 4 after the start of the infusion, 40 mg IV bolus of furosemide administered through a separate IV line, given slowly over 1 to 2 minutes."}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered 8 hours continuous IV infusion of D5W administered at the flow rate of 20 mL/H. At hour 4 after the start of the infusion, 40 mg IV bolus of furosemide administered through a separate IV line, given slowly over 1 to 2 minutes."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "23"}]}], "classes": [{"title": "Before start of infusion", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.2", "spread": "0.13"}, {"groupId": "OG001", "value": "0.2", "spread": "0.11"}]}]}, {"title": "0-2 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "12"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.1", "spread": "0.08"}, {"groupId": "OG001", "value": "0.1", "spread": "0.11"}]}]}, {"title": "2-4 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "14"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "0.3", "spread": "0.37"}, {"groupId": "OG001", "value": "0.1", "spread": "0.11"}]}]}, {"title": "4-5 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "21"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "7.9", "spread": "4.66"}, {"groupId": "OG001", "value": "8.2", "spread": "4.56"}]}]}, {"title": "5-6 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "19"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.3", "spread": "1.74"}, {"groupId": "OG001", "value": "3.7", "spread": "1.48"}]}]}, {"title": "6-7 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "21"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.8", "spread": "2.03"}, {"groupId": "OG001", "value": "2.7", "spread": "1.43"}]}]}, {"title": "7-8 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "21"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.0", "spread": "1.22"}, {"groupId": "OG001", "value": "1.7", "spread": "1.15"}]}]}, {"title": "8-10 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}, {"groupId": "OG001", "value": "20"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1.7", "spread": "1.28"}, {"groupId": "OG001", "value": "1.6", "spread": "1.00"}]}]}]}, {"type": "SECONDARY", "title": "Furosemide Plasma Concentrations", "description": "Summary of plasma concentrations by interval.", "populationDescription": "All randomized subjects who started study drug infusion in at least one treatment period. This is also known as the Intent to Treat (ITT) population. Data in this data set was analyzed based on randomized sequence of treatments.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL", "timeFrame": "Day 1: 4, 5, 6, 8, 10 hours", "groups": [{"id": "OG000", "title": "BMS-986231", "description": "BMS-986231 administered 8 hours continuous IV infusion at the dose of 12 \u03bcg/kg/min, corresponding to an infusion rate of 20 mL/H. At hour 4 after the start of the infusion, 40 mg IV bolus of furosemide administered through a separate IV line, given slowly over 1 to 2 minutes."}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered 8 hours continuous IV infusion of D5W administered at the flow rate of 20 mL/H. At hour 4 after the start of the infusion, 40 mg IV bolus of furosemide administered through a separate IV line, given slowly over 1 to 2 minutes."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "23"}]}], "classes": [{"title": "4 hours post-dose", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}, {"groupId": "OG001", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1605", "spread": "5384"}, {"groupId": "OG001", "value": "63.6", "spread": "140.3"}]}]}, {"title": "5 hours post-dose", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "20"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2049", "spread": "593.0"}, {"groupId": "OG001", "value": "2145", "spread": "653.2"}]}]}, {"title": "6 hours post-dose", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "21"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1122", "spread": "437.6"}, {"groupId": "OG001", "value": "1146", "spread": "466.8"}]}]}, {"title": "8 hours post-dose", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "21"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "426.8", "spread": "204.8"}, {"groupId": "OG001", "value": "476.6", "spread": "226.0"}]}]}, {"title": "10 hours post-dose", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "19"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "345.6", "spread": "386.6"}, {"groupId": "OG001", "value": "244.3", "spread": "164.3"}]}]}]}, {"type": "SECONDARY", "title": "Ratio Urinary Sodium (Na) to Urinary Furosemide at 8 Hours Post-start Infusion", "description": "Summary of urinary concentrations 0-4 hours after furosemide\n\nRatio = Cumulative Sodium Excretion / Cumulative Furosemide in Urine", "populationDescription": "Treated (per Protocol set) - All randomized participants who were given both study treatments and completed the study as per protocol. Participants are included in the treatment group they received in each period.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Ratio of Urinary Na:Urinary furosemide", "timeFrame": "0-4 hours after furosemide", "groups": [{"id": "OG000", "title": "BMS-986231", "description": "BMS-986231 administered 8 hours continuous IV infusion at the dose of 12 \u03bcg/kg/min, corresponding to an infusion rate of 20 mL/H. At hour 4 after the start of the infusion, 40 mg IV bolus of furosemide administered through a separate IV line, given slowly over 1 to 2 minutes."}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered 8 hours continuous IV infusion of D5W administered at the flow rate of 20 mL/H. At hour 4 after the start of the infusion, 40 mg IV bolus of furosemide administered through a separate IV line, given slowly over 1 to 2 minutes."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "21"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "6.1", "spread": "3.18"}, {"groupId": "OG001", "value": "10.1", "spread": "4.74"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "paramType": "Difference between drug and placebo", "paramValue": "-4.0", "dispersionType": "STANDARD_DEVIATION", "dispersionValue": "4.74"}]}, {"type": "SECONDARY", "title": "Number of Participants With Clinically Relevant Hypotension", "description": "Clinically relevant hypotension is defined as systolic blood pressure (SBP) \\< 90 mmHg or symptomatic hypotension during infusion", "populationDescription": "Safety set : All randomized participants who take at least 1 dose of double-blind study treatment. Participants were included in the treatment group they received in each period.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Number of participants", "timeFrame": "up to 8 hours", "groups": [{"id": "OG000", "title": "BMS-986231", "description": "BMS-986231 administered 8 hours continuous IV infusion at the dose of 12 \u03bcg/kg/min, corresponding to an infusion rate of 20 mL/H. At hour 4 after the start of the infusion, 40 mg IV bolus of furosemide administered through a separate IV line, given slowly over 1 to 2 minutes."}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered 8 hours continuous IV infusion of D5W administered at the flow rate of 20 mL/H. At hour 4 after the start of the infusion, 40 mg IV bolus of furosemide administered through a separate IV line, given slowly over 1 to 2 minutes."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "23"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With an Adverse Event (AE)", "description": "Clinically relevant hypotension is defined as systolic blood pressure (SBP) \\< 90 mmHg or symptomatic hypotension during infusion", "populationDescription": "Safety set : All randomized participants who take at least 1 dose of double-blind study treatment. Participants were included in the treatment group they received in each period.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Number of participants", "timeFrame": "up to 8 days", "groups": [{"id": "OG000", "title": "BMS-986231", "description": "BMS-986231 administered 8 hours continuous IV infusion at the dose of 12 \u03bcg/kg/min, corresponding to an infusion rate of 20 mL/H. At hour 4 after the start of the infusion, 40 mg IV bolus of furosemide administered through a separate IV line, given slowly over 1 to 2 minutes."}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered 8 hours continuous IV infusion of D5W administered at the flow rate of 20 mL/H. At hour 4 after the start of the infusion, 40 mg IV bolus of furosemide administered through a separate IV line, given slowly over 1 to 2 minutes."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "23"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "6"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With an Abnormal Clinical Laboratory Value", "description": "Number of participants who experienced an in-study abnormal clinical laboratory event under the category of Hematology, Chemistry or Urinalysis.", "populationDescription": "Safety set : All randomized participants who take at least 1 dose of double-blind study treatment. Participants were included in the treatment group they received in each period.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Number of participants", "timeFrame": "from first dose to 30 days post-last dose (ca. 5-8 weeks)", "groups": [{"id": "OG000", "title": "BMS-986231", "description": "BMS-986231 administered 8 hours continuous IV infusion at the dose of 12 \u03bcg/kg/min, corresponding to an infusion rate of 20 mL/H. At hour 4 after the start of the infusion, 40 mg IV bolus of furosemide administered through a separate IV line, given slowly over 1 to 2 minutes."}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered 8 hours continuous IV infusion of D5W administered at the flow rate of 20 mL/H. At hour 4 after the start of the infusion, 40 mg IV bolus of furosemide administered through a separate IV line, given slowly over 1 to 2 minutes."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "23"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Vital Signs - Blood Pressure", "description": "The change in baseline for vital signs was reported for each arm.", "populationDescription": "Safety set : All randomized participants who take at least 1 dose of double-blind study treatment. Participants were included in the treatment group they received in each period.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Day 1, 8 hours post-dose (end of infusion)", "groups": [{"id": "OG000", "title": "BMS-986231", "description": "BMS-986231 administered 8 hours continuous IV infusion at the dose of 12 \u03bcg/kg/min, corresponding to an infusion rate of 20 mL/H. At hour 4 after the start of the infusion, 40 mg IV bolus of furosemide administered through a separate IV line, given slowly over 1 to 2 minutes."}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered 8 hours continuous IV infusion of D5W administered at the flow rate of 20 mL/H. At hour 4 after the start of the infusion, 40 mg IV bolus of furosemide administered through a separate IV line, given slowly over 1 to 2 minutes."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "22"}]}], "classes": [{"title": "diastolic blood pressure", "categories": [{"measurements": [{"groupId": "OG000", "value": "-14.5", "spread": "9.99"}, {"groupId": "OG001", "value": "-0.6", "spread": "10.46"}]}]}, {"title": "systolic blood pressure", "categories": [{"measurements": [{"groupId": "OG000", "value": "-28.4", "spread": "15.60"}, {"groupId": "OG001", "value": "-4.9", "spread": "14.55"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Vital Signs - Heart Rate", "description": "The change in baseline for vital signs was reported for each arm.", "populationDescription": "Safety set : All randomized participants who take at least 1 dose of double-blind study treatment. Participants were included in the treatment group they received in each period.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "beats/min", "timeFrame": "Day 1, 8 hours post-dose (end of infusion)", "groups": [{"id": "OG000", "title": "BMS-986231", "description": "BMS-986231 administered 8 hours continuous IV infusion at the dose of 12 \u03bcg/kg/min, corresponding to an infusion rate of 20 mL/H. At hour 4 after the start of the infusion, 40 mg IV bolus of furosemide administered through a separate IV line, given slowly over 1 to 2 minutes."}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered 8 hours continuous IV infusion of D5W administered at the flow rate of 20 mL/H. At hour 4 after the start of the infusion, 40 mg IV bolus of furosemide administered through a separate IV line, given slowly over 1 to 2 minutes."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "22"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.5", "spread": "10.40"}, {"groupId": "OG001", "value": "-0.1", "spread": "8.08"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Vital Signs - Oxygen Saturation", "description": "The change in baseline for vital signs was reported for each arm.", "populationDescription": "Safety set : All randomized participants who take at least 1 dose of double-blind study treatment. Participants were included in the treatment group they received in each period.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "oxygen saturation percentage", "timeFrame": "Day 1, 8 hours post-dose (end of infusion)", "groups": [{"id": "OG000", "title": "BMS-986231", "description": "BMS-986231 administered 8 hours continuous IV infusion at the dose of 12 \u03bcg/kg/min, corresponding to an infusion rate of 20 mL/H. At hour 4 after the start of the infusion, 40 mg IV bolus of furosemide administered through a separate IV line, given slowly over 1 to 2 minutes."}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered 8 hours continuous IV infusion of D5W administered at the flow rate of 20 mL/H. At hour 4 after the start of the infusion, 40 mg IV bolus of furosemide administered through a separate IV line, given slowly over 1 to 2 minutes."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "22"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.0", "spread": "1.82"}, {"groupId": "OG001", "value": "0.0", "spread": "1.56"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Electrocardiograms (ECGs) - Mean Heart Rate", "description": "The change in baseline for ECGs was reported for each arm.", "populationDescription": "Safety set : All randomized participants who take at least 1 dose of double-blind study treatment. Participants were included in the treatment group they received in each period.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "beats/min", "timeFrame": "Day 1, 8 hours post-dose (end of infusion)", "groups": [{"id": "OG000", "title": "BMS-986231", "description": "BMS-986231 administered 8 hours continuous IV infusion at the dose of 12 \u03bcg/kg/min, corresponding to an infusion rate of 20 mL/H. At hour 4 after the start of the infusion, 40 mg IV bolus of furosemide administered through a separate IV line, given slowly over 1 to 2 minutes."}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered 8 hours continuous IV infusion of D5W administered at the flow rate of 20 mL/H. At hour 4 after the start of the infusion, 40 mg IV bolus of furosemide administered through a separate IV line, given slowly over 1 to 2 minutes."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "21"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.9", "spread": "7.97"}, {"groupId": "OG001", "value": "1.6", "spread": "7.61"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Electrocardiograms (ECGs) - PR, QRS Duration, QT, QTcF Intervals", "description": "The change in baseline for ECGs was reported for each arm.", "populationDescription": "Safety set : All randomized participants who take at least 1 dose of double-blind study treatment. Participants were included in the treatment group they received in each period.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "msec", "timeFrame": "Day 1, 8 hours post-dose (end of infusion)", "groups": [{"id": "OG000", "title": "BMS-986231", "description": "BMS-986231 administered 8 hours continuous IV infusion at the dose of 12 \u03bcg/kg/min, corresponding to an infusion rate of 20 mL/H. At hour 4 after the start of the infusion, 40 mg IV bolus of furosemide administered through a separate IV line, given slowly over 1 to 2 minutes."}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered 8 hours continuous IV infusion of D5W administered at the flow rate of 20 mL/H. At hour 4 after the start of the infusion, 40 mg IV bolus of furosemide administered through a separate IV line, given slowly over 1 to 2 minutes."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "21"}]}], "classes": [{"title": "PR Interval, Aggregate", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "15"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "2.0", "spread": "24.21"}, {"groupId": "OG001", "value": "-2.8", "spread": "12.17"}]}]}, {"title": "QRS Duration, Aggregate", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "21"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.9", "spread": "25.91"}, {"groupId": "OG001", "value": "2.2", "spread": "21.46"}]}]}, {"title": "QT Interval, Aggregate", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "21"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-9.1", "spread": "27.88"}, {"groupId": "OG001", "value": "-7.9", "spread": "16.95"}]}]}, {"title": "QTcF Interval, Aggregate", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "21"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-11.2", "spread": "26.90"}, {"groupId": "OG001", "value": "-5.1", "spread": "16.74"}]}]}]}, {"type": "SECONDARY", "title": "Telemetry", "description": "Telemetry data not collected.", "populationDescription": "Analysis population is 0, data not collected", "reportingStatus": "POSTED", "timeFrame": "Day 1, 8 hours post-dose", "groups": [{"id": "OG000", "title": "BMS-986231", "description": "BMS-986231 administered 8 hours continuous IV infusion at the dose of 12 \u03bcg/kg/min, corresponding to an infusion rate of 20 mL/H. At hour 4 after the start of the infusion, 40 mg IV bolus of furosemide administered through a separate IV line, given slowly over 1 to 2 minutes."}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered 8 hours continuous IV infusion of D5W administered at the flow rate of 20 mL/H. At hour 4 after the start of the infusion, 40 mg IV bolus of furosemide administered through a separate IV line, given slowly over 1 to 2 minutes."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Physical Examination - Body Weight", "description": "The change in baseline for physical examinations was reported for each arm.", "populationDescription": "Treated (per Protocol set) - All randomized participants who were given both study treatments and completed the study as per protocol. Participants are included in the treatment group they received in each period.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "kg", "timeFrame": "Day 1, 8 hours post-dose (end of infusion)", "groups": [{"id": "OG000", "title": "BMS-986231", "description": "BMS-986231 administered 8 hours continuous IV infusion at the dose of 12 \u03bcg/kg/min, corresponding to an infusion rate of 20 mL/H. At hour 4 after the start of the infusion, 40 mg IV bolus of furosemide administered through a separate IV line, given slowly over 1 to 2 minutes."}, {"id": "OG001", "title": "Placebo", "description": "Placebo administered 8 hours continuous IV infusion of D5W administered at the flow rate of 20 mL/H. At hour 4 after the start of the infusion, 40 mg IV bolus of furosemide administered through a separate IV line, given slowly over 1 to 2 minutes."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "20"}, {"groupId": "OG001", "value": "19"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.2", "spread": "0.77"}, {"groupId": "OG001", "value": "-0.5", "spread": "0.72"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "From first dose to 100 days post-last dose (up to ca. 4 months)", "eventGroups": [{"id": "EG000", "title": "BMS-986231", "description": "BMS-986231 administered 8 hours continuous IV infusion at the dose of 12 \u03bcg/kg/min, corresponding to an infusion rate of 20 mL/H. At hour 4 after the start of the infusion, 40 mg IV bolus of furosemide administered through a separate IV line, given slowly over 1 to 2 minutes.", "deathsNumAffected": 0, "deathsNumAtRisk": 23, "seriousNumAffected": 1, "seriousNumAtRisk": 23, "otherNumAffected": 6, "otherNumAtRisk": 23}, {"id": "EG001", "title": "Placebo", "description": "Placebo administered 8 hours continuous IV infusion of D5W administered at the flow rate of 20 mL/H. At hour 4 after the start of the infusion, 40 mg IV bolus of furosemide administered through a separate IV line, given slowly over 1 to 2 minutes.", "deathsNumAffected": 0, "deathsNumAtRisk": 23, "seriousNumAffected": 2, "seriousNumAtRisk": 23, "otherNumAffected": 3, "otherNumAtRisk": 23}], "seriousEvents": [{"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 23}]}, {"term": "Lower respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 23}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 23}]}, {"term": "Acute kidney injury", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 23}]}, {"term": "Chronic obstructive pulmonary disease", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 23}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 23}]}], "otherEvents": [{"term": "Lower respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 23}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 23}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 23}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 23}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 23}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 23}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "22.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 23}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 23}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "LTE60", "restrictiveAgreement": true}, "pointOfContact": {"title": "Bristol-Myers Squibb Study Director", "organization": "Bristol-Myers Squibb", "email": "Clinical.Trials@bms.com", "phone": "Please email:"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2019-04-15", "uploadDate": "2020-12-10T17:14", "filename": "Prot_000.pdf", "size": 1235659}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2020-01-22", "uploadDate": "2020-12-10T17:14", "filename": "SAP_001.pdf", "size": 469255}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01", "submissionTracking": {"firstMcpInfo": {"postDateStruct": {"date": "2021-01-06", "type": "ACTUAL"}}}}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M27583", "name": "Systolic Murmurs", "relevance": "LOW"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "T4202", "name": "Oculocerebral Syndrome With Hypopigmentation", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000005665", "term": "Furosemide"}], "ancestors": [{"id": "D000004232", "term": "Diuretics"}, {"id": "D000045283", "term": "Natriuretic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000049994", "term": "Sodium Potassium Chloride Symporter Inhibitors"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M8784", "name": "Furosemide", "asFound": "48 hours", "relevance": "HIGH"}, {"id": "M7411", "name": "Diuretics", "relevance": "LOW"}, {"id": "M26153", "name": "Sodium Potassium Chloride Symporter Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "NaAg", "name": "Natriuretic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}